最新医学別冊　新しい診断と治療のABC59/代謝5　肥満症

出版社： 最新医学社
発行日： 2009-01-25
分野： 臨床医学：一般  >  雑誌
雑誌名：
特集： 肥満症
電子書籍版： 2009-01-25
書籍・雑誌
≪全国送料無料でお届け≫
品切れ

5,500 円(税込)

電子書籍
章別単位での購入はできません
ブラウザ、アプリ閲覧

4,400 円(税込)

購入する

目次

  • 最新医学別冊　新しい診断と治療のABC59/代謝5　肥満症

    ―目次―

    特集　肥満症

    第1章　概念・定義と疫学
    　肥満と肥満症の定義 　
    　疫学-我が国の特徴- 　

    第２章　病因と病態生理
    　食欲コントロールシステムとその異常　
    　エネルギー消費と肥満 　
    　肥満遺伝子 　
    　肥満合併症とアディポサイトカイン 　
    　脂肪細胞の質的異常による肥満症 　
    　脂肪細胞の量的異常による肥満症

    第3章　診断
    　肥満症の分類とガイドライン 　
    　肥満症の診断基準 　
    　遺伝性肥満をめぐる最近の進歩 　
    　脂肪分析法

    第４章　管理･治療
    　肥満治療の目的と考え方 　
    　食事療法 　
    　運動療法 　
    　外科療法　
    　肥満症の薬物療法をめぐる最近の展望
    　メタボリックシンドロームと特定保健指導 　
    　医療経済

    座談会
    　肥満症の正しい理解とその対策

この書籍の参考文献

参考文献のリンクは、リンク先の都合等により正しく表示されない場合がありますので、あらかじめご了承下さい。

本参考文献は電子書籍掲載内容を元にしております。

第1章 概念・定義と疫学

P.15 掲載の参考文献
1) 肥満症診断基準検討委員会:新しい肥満の判定と肥満症の診断基準. 肥満研 6:18-28, 2000.
Medical*Online
2) 吉池信男, 他:Body Mass Index に基づく肥満の程度と糖尿病, 高血圧, 高脂血症の危険因子との関連-多施設共同研究による疫学的検討-. 肥満研 6:4-17, 2000.
Medical*Online
3) Nakamura T, et al:Contribution of visceral fat accumulation to the development of coronary artery disease in non-obese men. Atherosclerosis 107:239-246, 1994.
 
4) 日本肥満学会 肥満症治療ガイドライン作成委員会:メタボリックシンドロームの診断基準と治療の実際. 肥満症治療ガイドライン 2006. 肥満研 12 (臨時増刊号):42-48, 2006.
 
P.23 掲載の参考文献
1) A WHO Consultation on Obesity:Obesity preventing and managing the global epidemic. 1998; World Health Organization, Geneva, 1998
 
2) 厚生労働省:平成17年国民健康栄養調査報告, 第一出版株式会社, 東京, 2007.
 
3) OECD:Health Data2008 [Online]. Available:http://www.oecd.org/document/16/O,3343,en_2649_34631_2085200_1_1_1_37407,00.html (accessed November 15, 2008)
 
4) Miyoshi M, et al:Regional characteristics of secular changes in obesity-related lifestyle behavior in Japan. Anti-Aging Medicine 5 (2); 30-38, 2008.
 
5) Yoshiike N, et al:Epidemiology of obesity and public health strategies for its control in Japan. Asia Pac J Clin Nutr 11 (Suppl 8):S727-S731, 2002.
 
6) 吉池信男, 他:国民健康 栄養調査を活用した健康及び栄養水準に係る都道府県別ベンチマーク指標の検討. 厚生労働科学研究費補助金循環器等生活習慣病対策総合研究事業都道府県等の生活習慣病リスク因子の格差及び経年モニタリング手法に関する検討 (主任研究者 吉池信男) pp138-139, 2008.
 
7) メタボリックシンドローム診断基準検討委員会:メタボリックシンドロームの定義と診断基準. 日内会誌 94:188-203, 2005.
 

第2章 病因と病態生理

P.35 掲載の参考文献
1) 吉松博信:脳と食欲制御. 臨床糖尿病学, 内分泌糖尿病科 20:76-90, 2005.
 
2) 吉松博信:食行動調節における AMP キナーゼの役割, BIO Clinica 20:86-92, 2005.
 
3) Lam T K, et al:Hypothalamic sensing of fatty acids. Nat Neurosci 8:579-584, 2005.
PubMed
4) Cota D, et al:Hypothalamic mTOR signaling regulates food intake. Science 312:927-930, 2006.
PubMed
5) Pocai A, et al:Hypothalamic K (ATP) channels control hepatic glucose production. Nature 434:1026-1031, 2005.
PubMed
6) 吉松博信, 他:生体リズムと代謝調節異常. Annual Review 糖尿病代謝 内分泌 2007 28-34, 2007.
 
7) Gotoh K, et al:Glucagon-like peptide-1, corticotropin-releasing hormone, and hypothalamic neuronal histamine interact in the leptin-signaling pathway to regulate feeding behavior. FASEB J 19:1131-1133, 2005.
 
8) Hanada R, et al:Neuromedin U has a novel anorexigenic effect independent of the leptin signaling pathway. Nat Med 10:1067-1073, 2004.
 
9) 吉松博信:カンナビノイド作動薬. 分子糖尿病学のシンポ 2007 (矢崎義雄 監, 春日雅人, 他 編), p175-183, 金原出版, 東京, 2007.
 
10) 吉松博信:脳内モノアミンによる摂食行動調節機構. 日臨 61:57-63, 2003.
Medical*Online
11) Yoshimatsu H, et al:Hypothalamic neuronal histamine as a target of leptin in feeding behavior. Diabetes 48:2286-2291, 1999.
PubMed
12) Yoshimatsu H:Hypothalamic neuronal histamine regulates body weight through the modulation of diurnal feeding rhythm. Nutrition 24:827-831, 2008
PubMed
13) Masaki T, et al:Targeted disruption of histamine H1-receptor attenuates regulatory effects of leptin on feeding, adiposity, and UCP family in mice. Diabetes 50:385-391, 2001.
PubMed
14) Masaki T, et al:Involvement of hypothala mic histamine H1 receptor in the regulation of feeding rhythm and obesity. Diabetes 53:2250-2260, 2004.
 
15) Masaki T, et al:Central infusion of histamine reduces fat accumulation and upregulates UCP family in leptin-resistant obese mice. Diabetes 50:376-384, 2001.
PubMed
16) 吉松博信 他:摂食調節に関与する末梢シグナル受容体機構と求心神経路. 日臨 61:47-52, 2003. Yoshimatsu H, et al:Effects of hypothalamic lesion on pancreatic autonomic nerve activity in the rat. Brain Res 303:147, 1984
 
17) Masaki T, et al:Obesity in insulin receptor substrate-2-deficient mice:disrupted control of arcuate nucleus neuropeptides. Obes Res 12:878, 2004.
PubMed
18) Wang P Y, et al:Upper intestinal lipids trigger a gut-brain-liver axis to regulate glucose production. Nature 452:1012-1016, 2008.
PubMed
19) Yoshimatsu H, et al:Sympathetic nerve activity after discrete hypothalamic injection of L-glutamate. Brain Res 601:121-128, 1993.
PubMed
20) Pocai A, et al:A brain-liver circuit regulates glucose homeostasis. Cell Metab 1:53-61, 2005.
 
P.45 掲載の参考文献
1) 平成18年国民健康 栄養調査結果の概要について, 厚生労働省ホームページ, http://www-bm.mhlw.go.jp/houdou/2008/04/h0430-2.html
 
2) Levine J A, et al:Interindividual variation in posture allocation:possible role in human obesity. Science 307:584-586, 2005.
PubMed
3) Levine J A, et al:The role of free-living daily walking in human weight gain and obesity. Diabetes 57:548-554, 2008.
PubMed
4) 岡松優子, 他:褐色脂肪と白色脂肪, エネルギー代謝における役割. 分子細胞治療 5:330-336, 2006.
 
5) Cannon B, et al:Brown adipose tissue:function and physiological significance. Physiol Rev 84:277-359, 2003.
 
6) Enerback S, et al:Mice lacking mitochondrial uncoupling protein are cold-sensitive but not obese. Nature 387:90-94, 1997.
 
7) Bachman E S, et al:βAR signaling required for diet-induced thermogenesis and obesity resistance. Science 297:843-845, 2002.
 
8) Lowell B B, et al:Towards a molecular understanding of adaptive thermogenesis. Nature 404:652-660, 2000.
PubMed
9) Nagase I, et al:Expression of uncoupling protein in skeletal muscle and white fat of obese mice treated with thermogenic β3-adrenergic agonist J Clin Invest 97:2898-2904, 1996.
 
10) Omachi A, et al:Role of uncoupling protein 1 in the anti-obesity effect of β3-adrenergic agonist in the dog. Res Vet Sci 85:214-219, 2008.
 
11) Inokuma K, et al:Indispensable role of mitochondrial uncoupling protein 1 (UCP1) for anti-obesity effect of β3-adrenergic stimulation. Am J Physiol 290:E1014-E1021, 2006.
 
12) Inokuma K, et al:Uncoupling protein 1 is necessary for norepinephrine-induced glucose utilization in brown adipose tissue, Diabetes 54:1385-1391, 2005.
PubMed
P.56 掲載の参考文献
1) Zhang Y, et al:Positional cloning of the mouse obese gene and its human homologue. Nature 372:425-432, 1994.
PubMed
2) Ogawa Y, et al:Molecular cloning of rat obese cDNA and augmented gene expression in genetically obese Zucker fatty (fa/fa) rats. J Clin Invest 96:1647-1652, 1995.
PubMed
3) Considine R V, et al:Serum immunoreactive-leptin concentrations in normal-weight and obese humans. N Eugl J Med 334:292-295, 1996.
 
4) Lee G H, et al:Abnormal splicing of the leptin receptor in diabetic mouse. Nature 379:632-635, 1996.
PubMed
5) Vaisse C, et al:Leptin activation of Stat3 in the hypothalamus of wild type and ob/ob mice but not db/db mice. Nat Genet 14:95-97, 1996.
 
6) Ogawa Y, et al:Increased glucoses metabolism and insulin sensitivity in transgenic skinny mice overexpressing leptin. Diabetes 48:1822-1829, 1999.
PubMed
7) Satoh N, et al:the arcuate nucleus as a primary site of satiety effect of leptin in rats. Neurosci Lett 224:149-152, 1997.
 
8) Morton G J, et al:Central nervous system control of food intake and body weight. Nature 443 (7109):289-295, 2006.
PubMed
9) Satoh N, et al:Satiety effect and sympathetic activation of leptin are mediated by hypothalamic melanocortin system. Neurosci Lett 249:107-110, 1998.
PubMed
10) Pinto S, et al:Rapid rewiring of arcuate nucleus feeding circuits by leptin. Science 304:110-115, 2004.
PubMed
11) Aizawa-Abe M, et al:Pathophysiological role of leptin in obesity-related hypertension. J Clin Invest 105 (9):1243-1252, 2000.
PubMed
12) Satoh N, et al:Sympathetic activation of leptin via the ventromedical hypothalamus:leptin-induced increase in catecholamine secretion. Diabetes 48:1787-1793, 1999.
 
13) Agata J, et al:High plasma immunoreactive leptin level in essential hypertension. Am J Hypertens 10:1171-1174, 1997.
PubMed
14) Masuzaki H, et al:Glucose metabolism and insulin sensitivity in transgenic mice over-expressing leptin with lethal yellow agoutimutation:usefulness of leptin for the treatment of obesity-associated diabetes. Diabetes 48:1615-1622, 1999.
 
15) Bouloumie A, et al:Leptin induces oxidative stress in human endothelial cells. FASEB J 13 (10):1231-1238, 1999.
PubMed
16) Maingrette F, et al:Leptin increases lipoprotein lipase secretion by macrophages:involvement of oxidative stress and protein kinase C. Diabetes 52:2121-2128, 2003.
PubMed
17) Suganami E, et al:Leptin stimulates ischemia-induced retinal neovascularization:possible role of vascular endothelial growth factor expressed in retinal endothelial cells. Diabetes 53:2443-2448, 2004.
PubMed
18) Chiba T, et al:Leptin deficiency suppresses progression of atherosclerosis in apoE-deficient mice. Atherosclerosis. 2007 Mar 14
 
19) Ouchi N, et al:Novel modulator for endothelial adhesion molecules:adipocyte-derived plasma protein adiponectin. Circulation 100:2473-2476, 1999.
PubMed
20) Satoh N, et al:Leptin-to-adiponectin Ratio as a potential atherogenic index in obese type 2 diabetic patients. Diabetes Care 27:2488-2490, 2004.
PubMed
21) Kotani K, et al:Leptin:adiponectin ratio as an atherosclerotic index in patients with type 2 diabetes:relationship of the index to carotid intima-media thickness. Diabetologia 48 (12):2684-2268, 2005.
PubMed
22) Montague C T, et al:Congenital leptin deficiency is associated with severe early onset obesity in humans. Nature 387:903-907, 1997.
PubMed
23) Strobel A, et al:A leptin missense mutation associated with hypogonadism and morbid obesity. Nat Genet 18:213-215, 1999.
 
24) Clement K, et al:A mutation in the human leptin receptor gene causes obesity and pituitary dysfunction. Nature 392:398-401, 1998.
 
25) 佐藤哲子, 他:レプチン抵抗性の発現機序とレプチンの臨床応用. ホルモンと臨 52 (12):71-82, 2004.
 
26) Rahmouni K, et al:Selective resistance to central neural administration of leptin in agouti obese mice. Hypertension 39:486-490, 2002.
PubMed
P.70 掲載の参考文献
1) Maeda K, et al:Analysis of an expression profile of genes in the human adipose tissue. Gene 190:227-235, 1997.
PubMed
2) Maeda K, et al:cDNA cloning and expression of a novel adipose specific collagen-like factor, apM1 (Adipose Most abundant Gene transcript 1). Biochem Biophys Res Commun 221:286-289, 1996.
PubMed
3) Arita Y, et al:Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem Biophys Res Commun 257:79-83, 1999.
PubMed
4) Nishizawa H, et al:Androgens decrease plasma adiponectin, an insulin-sensitizing adipocyte-derived protein. Diabetes 51:2734-2741, 2002.
PubMed
5) Friedman J M, et al:Leptin and the regulation of body weight in mammals. Nature 395:763-770, 1998
PubMed
6) Shimomura I, et al:Enhanced expression of PAI-1 in visceral fat:possible contributor to vascular disease in obesity. Nature Med 2:800--802, 1996.
 
7) Hotamisligil G S, et al:Adipose expression of tumor necrosis factor-alpha:direct role in obesity-linked insulin resistance. Science 259:87-91, 1993.
PubMed
8) Lindsay R S, et al:Adiponectin and development of type 2 diabetes in the Pima Indian population. Lancet 360 (9326):57-58, 2002.
PubMed
9) Choi K M, et al:Serum adiponectin concentrations predict the developments of type 2 diabetes and the metabolic syndrome in elderly Koreans. Clin Endocrinol (Oxf) 61 (1):75-80, 2004.
PubMed
10) Mather K J, et al:Diabetes Prevention Program. Adiponectin, change in adiponectin, and progression to diabetes in the Diabetes Prevention Program. Diabetes 57 (4):980-986, 2008.
 
11) Kondo H, et al:Association of adiponectin mutation with type 2 diabetes:a candidate gene for the insulin resistance syndrome. Diabetes 51:2325-2328, 2002.
PubMed
12) Fruebis J, et al:Proteolytic cleavage product of 30-kDa adipocyte complement-related protein increases fatty acid oxidation in muscle and causes weight loss in mice. Proc Natl Acad Sci USA 98:2005-2010, 2001.
PubMed
13) Yamauchi T, et al:The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nat Med 7:941-946, 2001.
PubMed
14) Maeda N, et al:Diet-induced insulin resistance in mice lacking adiponectin/ACRP30. Nat Med 8:731-737, 2002.
PubMed
15) Maeda N, et al:PPAR (ligands increase expression and plasma concentration of adiponectin, an adipose-derived protein. Diabetes 50:2094-2099, 2001.
 
16) Maeda N, et al:PPARgamma ligands increase expression and plasma concentrations of adiponectin, an adipose-derived proteln. Diabetes 50 (9):2094-2099, 2001.
PubMed
17) Iwaki M, et al:Induction of adiponectin, a fat-derived antidiabetic and antiatherogenic factor, by nuclear receptors. Diabetes 52 (7):1655-1663, 2003.
PubMed
18) Kubota N, et al:Pioglitazone ameliorates insulin resistance and diabetes by both adiponectin-dependent and-independent pathways. J Biol Chem 281 (13):8748-8755, 2006.
PubMed
19) Hiuge A, et al:Effects of peroxisome proliferator-activated receptor ligands, bezafi-brate and fenofibrate, on adiponectin level. Arterioscler Thromb Vasc Biol 27 (3):635-641, 2007.
 
20) Oral E A, et al:Leptin-replacement therapy for lipodystrophy. N Engl J Med 346:570-578, 2002.
PubMed
21) Shimomura I, et al:Insulin resistance and diabetes mellitus in transgenic mice expressing nuclear SREBP-1c in adipose tissue:model for congenital generalized lipodystrophy. Genes Dev 12:3182-3194, 1998.
PubMed
22) Shimomura I, et al:Leptin reverses insulin resistance and diabetes mellitus in mice with congenital lipodystrophy. Nature 401:73-76, 1999.
PubMed
23) Li-Jun Ma, et al:Prevention of Obesity and Insulin Resistance in Mice Lacking Plasminogen Activator Inhibitor 1. Diabetes 53:336-346, 2004.
PubMed
24) Lopez-Alemany R, et al:Plasminogen activator inhibitor type-1 inhibits insulin signaling by competing with alphavbeta3 integrin for vitronectin binding. Eur J Biochem 270:814-821, 2003.
PubMed
25) Ouchi N, et al:Association of hypoad-iponectinemia with impaired vasoreactivity. Hypertension 42 (3):231-234, 2003.
PubMed
26) Ohashi K, et al:Adiponectin replenishment ameliorates obesity-related hypertension. Hypertension 47(6):1108-1116, 2006.
PubMed
27) Furukawa S, et al:Increased oxidative stress in obesity and its impact on metabolic syndrome. J Clin Invest 114 (12):1752-1761, 2004.
PubMed
28) Kurata A, et al:Blockade of Angiotensin II type-1 receptor reduces oxidative stress in adipose tissue and ameliorates adipocy-tokine dysregulation. Kidney Int 70 (10):1717-1724, 2006.
 
29) Fulita K, et al:Adiponectin protects against angiotensin II-induced cardiac fibrosis through activation of PPAR-alpha. Arterioscler Thromb Vasc Biol 28 (5):863-870, 2008.
 
30) Kamada Y, et al:Enhanced carbon tetra-chloride-induced liver fibrosis in mice lacking adiponectin. Gastroenterology 125:1796-1807, 2003.
 
31) Arita Y, et al:Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem Biophys Res Commun 257 (1):79-83, 1999.
PubMed
32) Ouchi N, et al:Novel modulator for endothelial adhesion molecules:adipocyte-derived plasma protein adiponectin. Circulation 100 (25):2473-2476, 1999.
PubMed
33) Kumada M, et al:Association of hypoadiponectinemia with coronary artery disease in men. Arterioscler Thromb Vasc Biol 23 (1):85-89, 2003.
PubMed
34) Pischon T, et al:Plasma adiponectin levels and risk of myocardial infarction in men. JAMA 291 (14):1730-1737, 2004.
PubMed
35) Ouchi N, et al:Adiponectin, an adipocyte-derived plasma protein, inhibits endothelial NF-kappaB signaling through a cAMP-dependent pathway. Circulation 102 (11):1296-1301, 2000.
PubMed
36) Matsuda M, et al:Role of adiponectin in preventing vascular stenosis. The missing link of adipo-vascular axis. J Biol Chem 277 (40):37487-37491, 2002.
 
37) Okamoto Y, et al:Adiponectin reduces atherosclerosis in apolipoprotein E-deficient mice. Circulation 106 (22):2767-2770, 2002.
PubMed
38) Kubota N, et al:Disruption of adiponectin causes insulin resistance and neointimal formation. J Biol Chem 277 (29):25863-25866, 2002.
PubMed
39) Yamauchi T, et al:Globular adiponectin protected ob/ob mice from diabetes and ApoE-deficient mice from atherosclerosis. J Biol Chem 278 (4):2461-2468, 2003.
PubMed
40) Landry D B, et al:Activation of the NF-B and IB system in smooth muscle cells after rat arterial injury. Induction of vascular cell adhesion molecule-1 and monocyte chemoattractant protein-1. Am J pathol 151:1085-1095, 1997.
 
41) Manduteanu I, et al:High glucose induces enhanced monocyte adhesion to valvular endothelial cells via a mechanism involving ICAM-1, VCAM-1 and CD18. Endothelium 6:315-324, 1999.
 
42) Peng HB, et al:Nitric oxide inhibits macrophage-colony stimulating factor gene transcription in vascular endothelial cells. J Biol Chem 270:17050-17055, 1995.
PubMed
43) Yudkin J S, et al:Inflammation, obesity, stress and coronary heart disease:is interleukin-6 the link? Atherosclerosis 148:209-214, 2000.
PubMed
44) Lavie L:Obstructive sleep apnea syndrome-an oxidative stress disorder. Sleep Medicine Review 7:35-51, 2003.
PubMed
45) Nakagawa Y, et al:Nocturnal reduction in circulating adiponectin concentrations related to hypoxic stress in severe obstructive sleep apnea-hypopnea syndrome. Am J Physiol Endocrinol Metab 294 (4):E778-784, 2008. 3
 
P.79 掲載の参考文献
1) 日本肥満学会肥満症治療ガイドライン作成委員会:肥満症治療ガイドライン 2006. 肥満研 12 (臨時増刊号):2006.
 
2) Fujioka S, et al:Contribution of intra-abdominal fat accumulation to the impairment of glucose and lipid metabolism. Metabolism 36 (1):54-59, 1987.
 
3) Matsuzawa Y, et al:Adiponectin and metabolic syndrome. ArterosclerThromb Vasc Biol 24 (1):29-33, 2004.
PubMed
4) Kuriyama H, et al:Coordinated regulation of fat-specific and liver-specific glycerol channels, aquaporin adipose and aquaporin 9. Dibetes 51 (10):2915-2921, 2002.
 
P.88 掲載の参考文献
1) Vgontzas AN:Sleep apneaand day-timesleepinenn and fatigue; relation to visceral fat, insulin resistance and hypercy-tokinemia. J Clin Endcrinol Metab 85:1151-1158, 2000.
 
2) 高橋真生:睡眠時無呼吸症候群. 治療学 41 (7), 2007.
Medical*Online
3) 永山大二:肥満の改善により腎機能, 尿蛋白が改善した糖尿病顕性腎症の2症例. 肥満研究 10 (2), 2004.
 
4) Saiki A, et al:Effect of weight loss using formula diet on renal function in obese patientrs with diabetic nephropathy. Int J Obesity 29:1115-1120, 2005.
 
5) 腰野富久:肥満に見られる整形外科疾患合併症 日臨 53:382-387, 1995.
 

第3章 診断

P.95 掲載の参考文献
1) 日本肥満学会肥満症治療ガイドライン作成委員会:肥満症治療ガイドライン 2006. 肥満研 12 臨時増刊号.
 
2) Hirsch J, et al:Methods for the determination of adipose cell size in man and animals. J Lipid Res 9:110, 1968.
PubMed
3) 松澤佑次, 他:新しい肥満の判定と肥満症の診断基準. 肥満研 6:18-28, 2000.
Medical*Online
4) Vague J:La differenciation sexuelle-facteur determinant de formes de I'obesite. Prese Med 30:339-340, 1947.
 
5) Kissebah A H, et al:Relationship of body fat distribution to metabolic complications of obesity. J Clin Endcrinol Metab 54:254-260, 1982.
 
6) Krotkiewski M, et al:Impact of obesity on metabolism in men and women-importance of regional adipose tissue distribution. J Clin Invest 72:1150-1162, 1983.
PubMed
7) Tokunaga K, et al:A novel technique for the determination of body fat by computed tomography. Int J Obes 7:437-453, 1983.
PubMed
8) Fujioka S, et al:Contribution of intra-abdominal fat accumulation to the impairment of glucose and lipid metabolism in human obesity. Metabolism 36 (1):54-59, 1987.
 
9) Tokunaga K, et al:Ideal body weight estimated by the body mass index for the lowest morbidity. Int J Obes 15:1-5, 1991.
PubMed
P.101 掲載の参考文献
1) Tokunaga K, et al:Ideal body weight estimated from the body mass index with the lowest morbidity. Int J Obes 15:1-5, 1991.
PubMed
2) Obesity. Preventing and managing the global epidemic. Report of a WHO consultation on obesity Genova. 3. Global prevalence and secular trends in obesity. 1997.
 
3) Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults. The evidence report. National Institutes of Health. National Heart, Lung and Blood Institute 1997.
 
4) 吉池信男, 他:BMIによって判定される肥満 やせの程度と合併症の頻度-国民栄養調査データの再解析-. 肥満研 4 (増刊):5-11, 1998.
 
5) McNeely M J, et al:Standard definition of overweight and central adiposity for determining diabetes risk in Japanese Americans. Am J Clin Nutr 74:101-107, 2001.
 
6) 日本肥満学会肥満症診断基準検討委員会:新しい肥満の判定と肥満症の診断基準. 肥満研 6:18-28, 2000.
Medical*Online
7) The Examination Committee of Criteria for "Obesity Disease" in Japan, Japan Society for Study of Obesity:New criteria for 'Obesity disease' in Japan. Circ J 66:987-992, 2002.
PubMed
8) McNeely M J, et al:Type 2 diabetes preva-1ence in Asian Americans. Results of a national health survey. Diabetes Care 27:66-69, 2004.
 
9) 生活習慣病予防研究会 編:生活習慣病のしおり, 社会保険出版社, 東京, 2004.
 
10) 日本肥満学会肥満症治療ガイドライン作成委員会:III. 診断基準肥満症治療ガイドライン 2006. 肥満研 12 (臨時増刊号):10-15, 2006.
 
P.108 掲載の参考文献
1) Maes H H, et al:Genetic and environmental factors in relative body weight and human adiposity. Behav Genet 27:325-351, 1997.
PubMed
2) Hill J O, et al:Environmental contributions to the obesity epidemic. Science 280:1371-1374, 1998.
 
3) West DB, et al:Dietary obesity in the mouse:interaction of strain with diet composition. Am J Physiol 268:R658-R665, 1995.
PubMed
4) Chung W K, et al:Molecular physiology of syndromic obesities in humans. Trends Endocrinol Metab 16:267-272, 2005.
PubMed
5) Vaisse C, et al:Melanocorin-4 receptor mutations are a frequent and heterogeneous cause of morbid obesity. J Clin Invest 106:253-262, 2000.
PubMed
6) Montague C T, et al:Congenital leptin deficiency is associated with severe early-on-set obesity in humans. Nature 387:903-908, 1997.
 
7) Clement K, et al:A mutation in the human leptin receptor gene causes obesity and pituitary dysfunction. Nature 392:398-401, 1998.
 
8) Farooqi I S, et al:Clinical spectrum of obesity and mutations in the melanocortin 4 receptor gene. N Eng J Med 348:1085-1095, 2003.
 
9) Clement K, et al:Genetics of obesity. Am J Pharmacogenetics 2:177-187, 2002.
 
10) Frayling T M, et al:A common variant in the FTO gene is associated with body mass index and predisposes to childhood and adult obesity. Science 316:889-894, 2007.
PubMed
11) Hotta K, et al:Variations in the FTO gene are associated with severe obesity in the Japanese. J Hum Genet 53:546-553, 2008.
PubMed
12) Tanabe A, et al:Functional single-nucleotide polymorphisms in the secretogranin III (SCG3) gene that form secretory granules with appetite-related neuropeptides are associated with obesity. J Clin Endocrinol Metab 92:1145-1154, 2007.
 
13) Yanagiya T, et al:Association of single-nucleotide polymorphisms in MTMR9 gene with obesity, Hum Mol Genet 16:3017-3026, 2007.
PubMed
14) Herbert A, et al:Acommon genetic variant is associated with adult and childhood obesity. Science 312:279-283, 2006.
 
15) Loos RJF, et al:Common variants near MC4R are associated with fat mass, weight and risk of obesity. Nat Genet 40:768-775, 2008.
 
16) Hotta K, et al:INSIG2 gene rs7566605 polymorphism is associated with severe obesity in the Japanese. J Hum Genet 53:857-862, 2008.
PubMed
17) Croft J B, et al:Obesity, hypertension, and and renal disease in relatives of Bardet-Biedl syndrome sibs. Am J Med Genet 36:37-42, 1990.
PubMed
18) Ansley S J, et al:Basal body dysfunction is a likely cause of pleiotropic Bardet-Biedl Syndrome. Nature 425:628-633, 2003.
PubMed
19) Collin GB, et al:Mutations in ALMS1 cause obesity, type 2 diabetes and neurosensory degeneration in Alstrom syndrome. Nat Genet 31:74-78, 2002.
PubMed
20) Kolehmainen J, et al:Cohen syndrome is caused by mutations in a novel gene, COH1, encoding a transmembraneprotein with a presumed role in vesicle-mediated sorting and intracellular protein transport. Am J Hum Genet 72:1359-1369, 2003.
 
21) Lower K M, et al:Mutations in PHF6 are associated with Borjeson-Forssman-Lehmann syndrome. Nat Genet 32:661-665, 2002.
PubMed
P.119 掲載の参考文献
1) メタボリックシンドローム診断基準検討委員会:メタボリックシンドロームの定義と診断基準 日内会誌 94:794-809, 2005.
 
2) Brozek J, el al:Densitometric analysis of body composition:revision of some quantitative assumptions. Ann NY Acad Sci 110:113-140, 1963.
 
3) 徳永勝人, 他:ヒト肥満症の脂肪組織に関する研究-CTスキャンによる脂肪組織の測定. 肥満研 2:144-145, 1982.
 
4) Tokunaga K, et al:A novel technique for the determination of body fat by computed tomography. Int J Obes 7:437-445, 1983.
PubMed
5) Mazess RB, et al:Dual-energy x-ray absorptiometry for total body and regional bone-mineral and soft-tissue composition. Am J Clin Nutr 51:1106-1112, 1990.
PubMed
6) 新井武志, 他:DEXA 法で測定した体脂肪量の臨床的意義. 第13回日本肥満学会記録 253-255, 1992.
 
7) Suzuki R, et al:Abdominal wall fat index, estimated by ultrasoundgraphy, for assessment of the ratio of visceral fat to subcutaneous fat in the abdomen. Am J Med 95:309-314, 1993.
 
8) Stark DD, et al:Nuclear magnetic resonance imaging of experimentally induced liver disease. Radiology 148:743-751, 1983.
PubMed
9) Seidell J C, et al:Imaging techniques for measuring adipose-tissue distribution-a comparison between computed tomography and 1.5T magnetic resonance. Am J Clin Nutr 51:953-957, 1990.
 
10) Fowler P A, et al:Total and subcutaneous adipose tissue in women:the measurement of distribution and accurate prediction of quantity by using magnetic resonance imaging. Am J Clin Nutr 54:18-25, 1991.
PubMed
11) Levenson H, et al:Fatty infiltration of the liver:quantification with phase-contrast MR imaging at 1.5 T vs biopsy. Am J Roentgenol 156:307-312, 1991.
 
12) Ross R, et al:Quantification of adipose tissue by MRI:relationship with anthropometric variables. J Appi Physiol 72:787-795, 1992.
 
13) de Ridder C M, et al:Body fat distribution in pubertal girls quantified by magnetic resonance imaging. Int J Odes Relat Metab Disord 16:443-449, 1992.
 
14) 日本肥満学会肥満症診断基準検討委員会:新しい肥満の判定と肥満症の診断基準. 肥満研 6:18--28, 2000.
 
15) The Examination Committee of Criteria for 'Obesity Disease:in Japan, Japan Society for Study of Obesity:New criteria for'obesity disease:in Japan. Circ J 66:987-992, 2002.
PubMed
16) Fujioka S, et al:Contribution of intra-abdominal fat accumulation to the impairment of glucose and lipid metabolism in human obesity. Metabolism 36:54-59, 1987.
 
17) Kanai H, et al:Close correlation of intra-abdominal fat accumulation to hypertension in obese women. Hypertension 16:484, 1990.
PubMed
18) Nakamura T, et al:Contribution of visceral fat accumulation to the development of coronary artery disease in non-obese men. Atherosclerosis 107:239-246, 1994,
 
19) 善積 透, 他:CTによる腹部脂肪分評価法の普及をめざして-標準的CT画像撮影条件の確立およびパソコン版脂肪面積計測ソフトウェアの開発-. 肥満研 6:81-87, 2000.
 
20) Chowdhury B, et al:A multicompartment body composition technique based on computerized tomography. Int J Obes 48:219-234, 1994.
 
21) 中村 正, 他:X線CT法. p209-214. 日臨 53 (特別号:肥満症) 1995.
 
22) Yoshizumi T, et al:Abddominal fat:Standardized technique for measurement at CT. Radiology 211:283-286, 1999.
 
23) 坂本要一, 他:中高年成人病健診受診者における体脂肪測定の有用性. 健康医 13:50-53, 1998.
 

第4章 管理・治療

P.130 掲載の参考文献
1) 厚生労働省健康局総務課生活習慣病対策室:平成17年国民健康栄養調査結果の概要. 栄養日本 12:23-42, 2007.
 
2) Nakamura T, et al:Magnitude of sustained multiple risk factors for ischemic heart disease in Japanese employees:a case-control study. JPn Circ J 65 (1):11-17, 2001.
PubMed
3) Spiegelman B M, et al:Obesity and the regulation of energy balance. Cell 104 (4):531-543, 2001,
PubMed
4) 上野浩晶, 他:神経系を介した摂食調節機構細胞工学 24 (5):462-465, 2005.
 
5) Tappy L:Thermic effect of food and sympathetic nervous system activity in humans. Reprod Nutr Dev 36 (4):391-397, 1996.
PubMed
6) Westerterp K R:Diet induced thermogenesis. Nutr Metab (Lond) 1 (1):5, 2004.
 
7) de Jonge L, et al:The thermic effect of food and obesity:a critical review, Obes Res 5 (6):622-631, 1997,
PubMed
8) Norris S L, et al:Long-term effectiveness of lifestyle and behavioral weight loss interventions in adults with type 2 diabetes:a meta-analysis. Am J Med 117 (10):762-774, 2004.
PubMed
9) Wing R, et al:Long-term weight loss main-tenance. Am J Clin Nutr 82 (1 Suppl):222S-225S, 2005.
 
10) Avenell A, et al:Systematic review of the long-term effects and economic consequences of treatments for obesity and implications for health improvement. Health Technol Assess 8 (21):iii-iv, 1-182, 2004.
 
11) Panzer C, et al:Aggressive diets and lipid responses. Curr Cardiol Rep 6 (6):464-473, 2004.
PubMed
12) 中村丁次:半健康人への栄養指導. 健康づくり指導者養成テキスト (栄養分野) p55-60. (財) 東京都健康推進財団, 東京, 1999.
 
P.138 掲載の参考文献
1) Sato Y, et al:Clinical aspects of physical exercise for diabetes/metabolic syndrome. Diabetes Res Clin Pract 77 (3) Suppl1:S87-S91, 2007.
 
2) 佐藤祐造, 他:糖尿病と耐糖能異常. 特定健診 保健指導に役立つ健康運動指導マニュアル (佐藤祐造, 他 編), pp156-165. 文光堂, 東京, 2008.
 
3) Chaston T B, et al:Factors associated with percent change in visceral versus subcutaneous abdominal fat during weight loss:finding from a systematic review. Int J Obes (Lond) 32 (4):619-628, 2008.
PubMed
4) Li G, et al:The long-term effect of interventions to prevent diabetes in the China Da Qing Diabetes Prevention Study:a 20-year follow-up study. Lancet 371:9626:1783-1789, 2008.
 
5) Fujii T, et al:The association of physical activity level characteristics and other life styles with obesity in Nagoya University alumni, Japan. Scand J Med Sci Sports 8:5762, 1998.
 
6) Lindstrom J, et al:Determinants for the effectiveness of lifestyle intervention in the Finnish Diabetes Prevention Study. Diabetes Care 31:857-862, 2008.
PubMed
7) Platat C, et al:Relationship of physical activity with metabolic syndrome features and low-grade inflammation in adolescents. Diabetologia 49:2078-2085, 2006.
PubMed
8) Hassinen M, et al:Cardiorespiratory fitness as a feature of metabolic syndrome in older men and women. Diabetes Care 31:1242-1247, 2008.
PubMed
9) Iwao N, et al:Regional difference in lipolysis caused by aβ-adrenergic agonist as determined by the microdialysis technique. Acta Physiol Scand 161:481-487, 1997.
 
10) Chatzinikolaou A, et al:Adipose tissue lipolysis is upregulated in lean and obese men during acute resistance exercise. Diabetes Care 31:1397-1399, 2008.
PubMed
11) Ravussin E:Physiology. A Neat way to control weight? Science 307:530-531, 2005.
PubMed
12) 佐藤祐造:高齢糖尿病の運動処方ガイドライン, 老年医学 update 2008-2009 (日本老年医学会誌編集委員会 編), pp48-55. メジカルビュー社, 東京, 2008.
 
13) Misra A, et al:Effect of supervised progresslve resistance-exercise training protocol on insulin sensitivity, glycemia, lipids, and body composition in Asian Indians with type 2 diabetes. Diabetes Care 31:1282-1287, 2008.
PubMed
14) Kubota M, et al:Mechanical horseback riding improves insulin sensitivity in elder diabetic patients. Diabetes Res Clin Pract 71:124-130, 2006.
PubMed
15) Petersen A M W, et al:The anti-inflammatory effect of exercise. J Appl Physiol 98:1154-1162, 2005.
 
16) 日本肥満学会編:肥満症治療ガイドライン 2006. 肥満研 12 (Suppl):2-89, 2006.
 
17) 和田昌樹, 他:太極拳の運動生理学的解析-%HRreserve を用いた検討-. 臨床スポーツ医学 18:933-938, 2001.
 
18) Orr R, et al:Mobility impairment in type 2 diabetes:Association with muscle power and effect of Tai Chi intervention. Diabetes Care 29:2120-2122, 2006.
PubMed
19) Trenell M I, et al:Increased daily walking improves lipid oxidation without changes in mitochondrial function in type 2 diabetes. Diabetes Care 31:1644-1649, 2008.
PubMed
20) Ford E S, et al:Metabolic syndrome and incident diabetes:Current state of the evidence. Diabetes Care 31:1898-1904, 2008.
PubMed
P.145 掲載の参考文献
1) Buchwald H, et al:Bariatric surgery world-wide 2003. Obes Surg 14:1157-1164, 2004.
 
2) National Institutes of Health Consensus Development Conference Panel:Gastrointestinal surgery for severe obesity. Ann Intern Med 115:956-961, 1991.
PubMed
3) Lee W J, et al:Bariatric surgery:Asia-Pacific perspective. Obes Surg 15:751-757, 2005.
 
4) Cohen R V, et al:Duodenal-jejunal bypass for the treatment of type 2 diabetes in patients with body mass index of 22-34kg/m2:a report of 2 cases. Surg Obes Relat Dis 3:195-197, 2007.
 
5) DePaula A L, et al:Laparoscopic treatment of type 2 diabetes mellitus for patients with a body mass index less than 35. Surg Endosc 22:706-716, 2008.
PubMed
6) Genco A, et al:BioEnterics intragastric balloon:the Italian experience with 2,515 patients. Obes Surg 15:1161-1164, 2005.
PubMed
7) Fogel R, et al:Clinical experience of transoral suturing for an endoluminal vertical gastroplasty:1-year follow-up in 64 patients. Gastrointest Endosc 68:51-58, 2008.
PubMed
8) Rodriguez-Grunet L, et al:First human experience with endoscopically delivered and retrieved duodenal-jejunal bypass sleeve. Surg ObesRelat Dis 4:55-59, 2008
 
9) Deitel M, et al:Reporting weight loss 2007. Obes Surg 17:565-568, 2007.
PubMed
10) Buchwald H, et al:Bariatric surgery:a systematic review and meta-analysis. JAMA 292:1724-1737, 2004.
PubMed
11) Frigg A, et al:Reduced in co-morbidities 4 years after laparoscopic adjustable gastric banding. Obes Surg 14:216--223, 2004.
 
12) Dixon J B, et al:Adjustable gastric banding and conventional therapy for type 2 diabetes:a randomized controlled trial. JAMA 299:316-323, 2008.
PubMed
13) Adams T D, et al:Long-term mortality after gastric bypass surgery. N Engl J Med 357:753-761, 2007.
PubMed
14) Busetto L, et al:Comparative long-term mortality after laparoscopic adjustable gastric banding versus nonsurgical controls. Surg Obes Relat Dis 3:496-502, 2007.
PubMed
15) Kasama K, et al:Has laparoscopic bariatric surgery been accepted in Japan?:the experience of a single surgeon. Obes Surg (in press) .
 
16) 北野正剛, 他:内科治療抵抗性肥満症に対する内視鏡的胃内バルーン留置療法の経験. Gastroenterol Endosc 47:2197-2201, 2005.
 
17) Ohta M, et al:Initial Japanese experience with intragastric balloon placement. Obes Surg (in press) .
 
18) 太田正之, 他:高度肥満患者に対する腹腔鏡下調節性胃バンディング術後の体重減少と併存疾患改善効果. 日消外会誌 41:599-604, 2008.
 
19) 日本肥満学会肥満症治療ガイドライン作成委員会:外科療法日本肥満学会肥満症治療ガイドライン2006, 肥満研究12巻増刊, p40-41. 協和企画, 東京, 2006.
 
20) 三学会合同委員会:内視鏡および内視鏡外科肥満治療法における三学会合同委員会合意事項と適応指針. 肥満研究12巻3号JASSO ニュース, p7-8. 協和企画, 東京, 2006.
 
P.151 掲載の参考文献
1) Melnikova I C, et al:Anti-obesity therapies. Nat Rev Drug Discov 5:369-370, 2006.
 
2) Dixon J B, et al:Adjustable gastric banding and conventional therapy for type 2 diabetes:a randomized controlled trial. JAMA 299:316-323, 2008.
PubMed
3) Unger R H:Minireview:weapons of lean body mass destruction:the role of ectopic lipids in the metabolic syndrome. Endocrinology 144:5159-5165, 2003.
PubMed
4) Brown M S, et al:Selective versus total insulin resistance:A pathogenic paradox. Cell Metab 7:95-96, 2008
PubMed
5) Unger R H:Reinventing type 2 diabetes:pathogenesis, treatment and prevention. JAMA 299:1185-1187, 2008
PubMed
6) Farrigan C, et al:Obesity market review. Nat Rev Drug Discov 1:257-258, 2002.
 
7) 吉田俊秀:肥満の薬物療法 治療 90:1701-1707, 2008
Medical*Online
8) 肥満症治療ガイドライン 2006:薬物療法. 肥満研究 12 (臨時増刊号):30-32, 2006.
 
9) James W, et al:Effect of sibutramine on weight maintenance after weight loss:a randomized trail Lancet 356:2119-2125, 2000.
 
10) Tomlinson J W, et al:Mechanisms of disease:Selective inhibition of 11beta-hydrox-ysteroid dehydrogenase type 1 as a novel treatment for the metabolic syndrome. Nat Clin Pract Endocrinol Metab 1:92-99, 2005.
 
11) Grundy S M:Drug therapy of the metabolic syndrome:minimizing the emerging crisis in polypharmacy. Nat Rev Drug Discov 5:295-309, 2006.
PubMed
12) Flier J S, et al:What Fuels Fat? Sci Am 297:46-57, 2007.
 
P.166 掲載の参考文献
1) 矢野栄二:健康診断の有効性と有用性. EBM健康診断第2版 p2-14. 医学書院, 東京, 2003.
 
2) 厚生科学審議会地域保健健康増進栄養部会:「健康日本21」中間評価報告書. 2007年4月10日厚生労働省
 
3) メタボリックシンドローム診断基準委員会:メタボリックシンドロームの定義と診断基準. 日内会誌 94:188-203, 2005,
 
4) Knowler W C, et al:Diabetes Prevention Program Resarch Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 346 (6):393-403, 2002.
PubMed
5) Wadden T A, et al:Efficacy of lifestyle modification for long-term weight control. Obes Res 12:151-162, 2004.
 
6) 村本あき子, 他:ウェスト周囲径90cm以上の女性に対する生活習慣介入研究-ウェスト周囲径3cm縮小の効果-. 肥満研 13 (1):60-67, 2007.
 
7) 厚生労働省健康局:標準的な健診保健指導プログラム. 平成19年4月
 
8) 厚生労働省保険局:特定健康診査特定保健指導の円滑な実施に向けた手引き. 平成19年7月
 
9) 門脇 孝, 他 編メタボリックシンドロームリスク管理のための健診保健指導ガイドライン. 南山堂, 東京, 2008.
 
10) 津下一代:メールでの健康相談～積極的支援の補助ツールとしての可能性～. テレメンタリング. 中山書店, 東京, 2007.
 
11) 津下一代:相手の心に届く保健指導のコツ. 東京法規出版, 東京, 2007.
 
12) 厚生労働省健康局総務課生活習慣病対策室:禁煙支援マニュアル, 2006.
 
13) NPO法人日本健康運動指導士会:特定保健指導における運動指導マニュアル. サンライフ企画, 東京, 2007.
 
P.172 掲載の参考文献
1) 徳永勝人, 他:原発性肥満と肥満症. 最新内科学大系6. 代謝疾患 1 肥満症, 臨床栄養 (垂井清一郎, 他 編). p107-127. 中山書店, 東京, 1995.
 
2) 国民衛生の動向. 厚生の指標 55:2008
 
3) National Health and Medical Research Council:Economic issues in the prevention and treatment of overweight and obesity. p85-95. Australian Government Publishing Service, Canberra, 1997.
 
4) Levy E, et al:The economic cost of obesity:the French situation. Int J Obes 19:788-793, 1995,
 
5) Seidel J, et al:Obesity in Europe. Pharmaco Economics 5 (Suppl):38-44, 1994.
 
6) Colditz G A:Economic costs of obesity. Am J Clin Nutr 55:503S-507S, 1992.
PubMed
7) World Health Organization:Obesity. Preventing and managing the global epidemic. Geneva, 1998.
 
8) Thompson D, et al:The medical-care cost burden of obesity. Obes Rev 2:189-197, 2001.
PubMed
9) Kuriyama S, et al:Medical care expenditure associated with body mass index in Japan:the Osaki Study. Int J Obes Relat Metab Disord 26:1069-1074, 2002.
 
10) 藤岡滋典, 他:日本人のBMIによる肥満の頻度と合併症. 肥満研 4 (supple):120, 1998.
 
11) 徳永勝人, 他:日本における肥満の医療経済-わが国における高コレステロール血症の頻度とそれに要する費用. 肥満研 5:94-97, 1999.
 
12) 松澤佑次, 他:新しい肥満の判定と肥満症の診断基準. 肥満研 6:18-28, 2000.
Medical*Online
13) National Insutitute of Health:Clinical guidlines in the identification and treatment of overweight and obesity in adults. NIH, 1998.
 
14) 井上修二:厚生省 日本肥満学会共同研究-肥満の疫学的研究. 肥満研 4:1-3, 1998.
 
15) Fujioka S, et al:Contribution of intra-abdominal fat accumulation to the impairment of glucose and lipid metabolism in human obesity. Metabolism 36:54-59, 1987.
 
16) 徳永勝人, 他:内臓脂肪症候群. 日内会誌 81:1831-1835, 1992.
 
17) Nakamura T, et al:Contribution of visceral fat accumulation to the development of coronary artery disease in non-obese men. Atherosclerosis 107:239-246, 1994.
 
18) 日本肥満学会肥満症治療ガイドライン作成委員会:肥満症治療ガイドライン 2006. 肥満研 12 臨時増刊号, 2006.
 
19) Oster G, et al:Life time health and economic benefits of weight loss among obese persons. Am J Public Health 89:1536-1542, 1999.
 
20) 富永典子, 他:肥満教室が外来医療費に及ぼす影響について. 肥満研 10:68-77, 2004.
 

書評

最近チェックした商品履歴

Loading...